16.34
16.34 (0%)
As of Apr 17, 2025
Newamsterdam Pharma Co N.V. [NAMS]
Source:
Company Overview
Newamsterdam Pharma Co N.v. is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated.
| Country | Netherlands |
| Headquarters | naarden, netherlands |
| Phone Number | 31 (0) 35 206 2971 |
| Industry | manufacturing |
| CEO | Dr. Michael Davidson |
| Website | www.newamsterdampharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $45.6 |
| Operating Profit | $-176.3 |
| Net Income | $-241.6 |
| Net Cash | $438.1 |
Profit Ratios
| Gross Margin | $45.6 |
| Operating Margin | -386.9 |
| Profit as % of Revenues | -18.9% |
| Profit as % of Assets | -39.9% |
| Profit as % of Stockholder Equity | -31.9% |
Management Effectiveness
| Return on Equity | -31.9% |
| Return on Assets | -27.9% |
| Turnover Ratio | 7.5% |
| EBITA | $-176.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $864.6 |
| Total Liabilities | $107.1 |
| Operating Cash Flow | $-158.6 |
| Investing Cash Flow | $-62.8 |
| Financing Cash Flow | $659.5 |
